Cadence has announced a revenue target of $5.9B–$6B by 2026, attributing this growth to the increasing demand for its AI-driven design solutions and a boosted backlog.

Halozyme has outlined a revenue target of $1.71 billion to $1.81 billion by 2026, driven by the expansion of its pipeline with new subcutaneous technologies.

Caesars anticipates a 20% growth in digital top-line revenue and a record $85 million in digital EBITDA, with group business offsetting leisure softness.